文献速递前列腺癌膀胱癌与上尿路尿路上皮癌肾癌与肾肿瘤

泌尿肿瘤手术中血栓与出血的操作特异性风险:系统综述与荟萃分析

Procedure-specific Risks of Thrombosis and Bleeding in Urological Cancer Surgery: Systematic Review and Meta-analysis.
PubMed 文献 · Eur Urol · 2017-03-23

该系统综述与荟萃分析纳入71项观察性研究,评估14种泌尿肿瘤手术术后4周内症状性静脉血栓栓塞症(VTE)与需再手术出血的基线风险,证据质量在前列腺切除与膀胱切除多为中等,其他手术低或极低;不同手术VTE风险差异大,出血风险总体较低。

要点

  • 膀胱切除术后VTE风险高(风险组间2.6-11.6%),出血风险低(0.3%)。
  • 机器人前列腺切除无盆腔淋巴结清扫(PLND)VTE风险0.2-0.9%,开放前列腺切除扩大PLND为3.9-15.7%。
  • 肾脏手术低危患者VTE风险0.7-2.9%,高危患者2.6-11.6%,出血风险0.1-2.0%。

核心结论

  • 部分手术(如开放与机器人膀胱切除)需要延长血栓预防,而其他手术(如低危患者无PLND的机器人前列腺切除)则不需要。
  • 对于「临界」手术,决策将取决于对VTE与出血的价值观和偏好。

研究设计与样本

  • 系统综述与荟萃分析,纳入71项报告14种泌尿肿瘤手术的当代观察性研究。
  • 采用偏倚风险最低的研究,并考虑血栓预防使用与随访时长,推导术后4周内基线风险的最佳估计。
  • 使用GRADE方法评估证据质量。

主要发现

  • 前列腺切除与膀胱切除的证据质量一般为中等,其他手术为低或极低。
  • 血栓预防时长高度可变。
  • 膀胱切除术后VTE风险高(风险组间2.6-11.6%),出血风险低(0.3%)。
  • 前列腺切除术后VTE风险因术式而异:无PLND的机器人前列腺切除为0.2-0.9%,开放前列腺切除扩大PLND为3.9-15.7%;出血风险0.1-1.0%。
  • 肾脏手术后VTE风险低危患者0.7-2.9%、高危患者2.6-11.6%;出血风险0.1-2.0%。

临床怎么用

  • 原文未据此给出推荐。

局限性

  • 证据质量在前列腺切除与膀胱切除一般为中等,其他手术为低或极低。
  • 血栓预防时长高度可变。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

CONTEXT: Pharmacological thromboprophylaxis involves balancing a lower risk of venous thromboembolism (VTE) against a higher risk of bleeding, a trade-off that critically depends on the risks of VTE and bleeding in the absence of prophylaxis (baseline risk). OBJECTIVE: To provide estimates of the baseline risk of symptomatic VTE and bleeding requiring reoperation in urological cancer surgery. EVIDENCE ACQUISITION: We identified contemporary observational studies reporting symptomatic VTE or bleeding after urological procedures. We used studies with the lowest risk of bias and accounted for use of thromboprophylaxis and length of follow-up to derive best estimates of the baseline risks within 4 wk of surgery. We used the GRADE approach to assess the quality of the evidence. EVIDENCE SYNTHESIS: We included 71 studies reporting on 14 urological cancer procedures. The quality of the evidence was generally moderate for prostatectomy and cystectomy, and low or very low for other procedures. The duration of thromboprophylaxis was highly variable. The risk of VTE in cystectomies was high (2.6-11.6% across risk groups) whereas the risk of bleeding was low (0.3%). The risk of VTE in prostatectomies varied by procedure, from 0.2-0.9% in robotic prostatectomy without pelvic lymph node dissection (PLND) to 3.9-15.7% in open prostatectomy with extended PLND. The risk of bleeding was 0.1-1.0%. The risk of VTE following renal procedures was 0.7-2.9% for low-risk patients and 2.6-11.6% for high-risk patients; the risk of bleeding was 0.1-2.0%. CONCLUSIONS: Extended thromboprophylaxis is warranted in some procedures (eg, open and robotic cystectomy) but not others (eg, robotic prostatectomy without PLND in low-risk patients). For "close call" procedures, decisions will depend on values and preferences with regard to VTE and bleeding. PATIENT SUMMARY: Clinicians often give blood thinners to patients to prevent blood clots after surgery for urological cancer. Unfortunately, blood thinners also increase bleeding. This study provides information on the risk of clots and bleeding that is crucial in deciding for or against giving blood thinners.

来源:Eur Urol,查看原文。版权归原作者所有。

引用

  1. Tikkinen KAO, Craigie S, Agarwal A, et al. Procedure-specific Risks of Thrombosis and Bleeding in Urological Cancer Surgery: Systematic Review and Meta-analysis. Eur Urol. 2017. PMID: 28342641. doi:10.1016/j.eururo.2017.03.008

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。